Know Cancer

or
forgot password

The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)


Phase 3
20 Years
65 Years
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)


Inclusion Criteria:



- Age 20 to 65

- Hematopoietic WBC ≥ 4,000/mm^3 Platelet ≥ 100,000/mm^3 Hemoglobin ≥ 11.0 g/dL

- Hepatic AST and ALT ≤ 40 U/L Total bilirubin ≤ 1.5 mg/dL

- Renal BUN ≤ 25 mg/dL Creatinine ≤ 1.5 mg/dL

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Relapse-free survival

Outcome Time Frame:

recurrence and survival will be collected for 5 years after surgery

Safety Issue:

No

Principal Investigator

Hiroki Koyama, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Osaka Medical Center for Cancer and Cardiovascular Diseases

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

91023033

NCT ID:

NCT00152178

Start Date:

July 1996

Completion Date:

August 2008

Related Keywords:

  • Breast Cancer
  • Breast Cancer
  • Breast Neoplasms

Name

Location